Megimmuno Swiss Pharmaceutical Technologies SA is private biopharmaceutical company duly organized and existing under the laws of Switzerland, and having a registered office at Avenue D’Ouchy 18, CH-1006 Lausanne, Switzerland.
Our objective is to sell our developed modifier of the immune system IM-1 to the industrial customer - Pharma market players. In order to reduce cost and timing of project commercialization process we made the decision to bring IM-1 to the market for new technologies for veterinary medicines and animal health products (instead of human pharmaceutical market).
We are currently seeking to raise additional funds to expand our GLP trial program to include additional indications in immune-related diseases. Please find below key facts about our projects evaluation. To learn more - please contact us directly.
Our stage of development
We have already passed all the main stages of R&D:
Dose formulation and stability tests, etc.)
Today we are absolutely ready to enter the next stage of product development – GLP certification process in order to prove the unique properties and effectiveness of IM-1, estimate its commercial value and commercialize our product with reliable strategic partner.
We identify our potential customers as medium and big size pharmaceutical companies producers of drugs for veterinary medicine.
Our customers are market players, who wish to beat the competition, making a breakthrough on the market and bring the new innovative drug which will become the blockbuster on the veterinary drug market.
We are sure that IM-1 will strategically complement their own line of development, enhance and strengthen position in the treatment of autoimmune diseases, adding to company's portfolio a promising new drug for s of ystemic and targeted therapies of animals.
Immunomodulators are becoming very popular in the worldwide health industry as people start to realize the importance of a healthy immune system in the maintenance of health and the prevention and recovery of disease. This leads to a significant raise of interest to new immunomodulation technologies and drugs from the side of big pharma as well as new developing pharmaceutical companies.
The global immunomodulators market was estimated to be $145.9 billion in 2010, and will reach $259.3 billion in 2017.
Business strategy: veterinary medicine market
Our business strategy to bring IM-1 to the market for new technologies for veterinary medicines and animal health products (instead of human pharmaceutical market) was chosen in order to reduce cost and timing of project commercialization process we made the decision.
The animal medicines and vaccines sector is estimated to represent a global market of $22 billion and expected to grow at 5.7% compound annual growth, faster than the market for human medicines. While the market is much smaller than the market of human medicines, there is also a much lower cost of entry, allowing drugs to be developed and brought to market faster, cheaper and with higher margins than those enjoyed by Big Pharma.